Project Grant R01HL183876
Award Date 7/1/26
Completion Date 3/31/31
Dollars Obligated $737K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baton Rouge, LA 70808, USA
Similar Awards
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Johns Hopkins University a Project Grant of $248,919 (awarded June 1, 2026; completion April 30, 2029) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate muscle metabolism and exercise intolerance in patients with heart failure and preserved ejection fraction (HFpEF). The research will employ a novel interleaved magnetic resonance spectroscopy/magnetic resonance...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Texas Southwestern Medical Center a $249,000 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) effective August 1, 2025, through June 30, 2028, to conduct research investigating the mechanisms of dyspnea on exertion (DOE) and exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF). The research will examine how obesity-related mechanical...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $169,020 in Project Grant funding to the University of Pennsylvania, effective August 1, 2025, through June 30, 2027, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research investigating one-carbon metabolism defects in heart failure, with the primary deliverable being scientific research outputs aimed at understanding the relationship between aberrant cardiac...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $1.49 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 18, 2025, with completion targeted for May 31, 2029. The grant funds research investigating combination therapy using hydrogen sulfide (H2S) donors and glucagon-like peptide-1 (GLP-1) agonists to treat heart failure with preserved ejection fraction (HFpEF)....
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pennsylvania a Project Grant totaling $169,020.00 under the Cardiovascular Diseases Research program (CFDA 93.837) beginning August 1, 2025 and concluding June 30, 2027. This research grant funds a comprehensive investigation into the pathophysiologic mechanisms linking obesity and type 2 diabetes to coronary microvascular defects in heart failure with preserved ejection fraction...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, Los Angeles a $741,473 Project Grant (CFDA 93.837—Cardiovascular Diseases Research) on June 15, 2026, with a completion date of March 31, 2030. This award funds mechanistic research into diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF), a condition characterized by abnormal calcium cycling and myofilament dysfunction. The research will...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a Project Grant of $614,843 effective May 1, 2026, through February 28, 2031, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a research investigation examining the relationship between indexed exercise blood pressure (systolic blood pressure normalized to oxygen consumption during exercise) and adverse vascular and ventricular remodeling in...
- Federal Grant Award Summary Michigan Technological University received a $589,998 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2028. The award supports research investigating cardiac sensory and sympathetic nerve dysregulation in hypertrophic cardiomyopathy (HCM), a genetic heart disease affecting approximately 1 in 500 individuals and representing the...
- Federal Grant Award Summary Wake Forest University Health Sciences received a $999,110 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with a completion date of May 31, 2030. The award funds a research initiative titled "Cellular Heterogeneity in Mitochondrial Calcium Dynamics in Heart Failure," which addresses a critical gap in understanding heart failure with preserved...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Johns Hopkins University a $638,176 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) effective May 1, 2026 through February 28, 2029 to conduct basic research investigating thrombospondin-1 (TSP-1) as a therapeutic target for heart failure with preserved ejection fraction (HFpEF). The research will identify mechanisms underlying cardiac structural changes in HFpEF through sex-specific...